Secondary Marketplace / Trade Private Companies / Buy and Sell Endeavor BioMedicines Stock
Endeavor BioMedicines Endeavor BioMedicines Stock
$676.04MM
Series C Valuation, Apr 2024
Register To Buy and Sell Private Company Shares
For more details on private stock price information, financing and valuation for Endeavor BioMedicines, register or login.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Sign in

Endeavor BioMedicines Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Endeavor BioMedicines Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
04/24/2024 Series C $132.58MM $xx.xx $676.04MM --
Price per Share
$xx.xx
Shares Outstanding
20,320,618
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2
Key Investors
--
02/07/2022 Series B $101MM $xx.xx $353.01MM --
Price per Share
$xx.xx
Shares Outstanding
21,415,997
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2
Key Investors
--
01/07/2021 Series A-1 $672,991.65 $xx.xx $117.27MM --
Price per Share
$xx.xx
Shares Outstanding
997,025
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
5.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2
Key Investors
--
01/07/2021 Series A-2 $623,966.61 $xx.xx $117.27MM --
Price per Share
$xx.xx
Shares Outstanding
499,173
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
5.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2
Key Investors
--
01/07/2021 Series A-3 $60.7MM $xx.xx $117.27MM --
Price per Share
$xx.xx
Shares Outstanding
23,917,780
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2
Key Investors
--
Company Details
Endeavor BioMedicines is a biotechnology company that is striving to discover new ways to treat patients who have life-threatening diseases. The company is working toward that goal by aiming to combat the drivers of fibrosis and oncology, which are both areas of medicine that have unmet needs. Endeavor BioMedicines was founded in 2018 by John Hood and Miguel de los Rios and is headquartered in San Diego, CA. In addition to looking for treatments that alleviate symptoms, Endeavor BioMedicines is seeking ways to reverse the effects of terminal illnesses.
Founded
2018
Post-Money Valuation 3
$676.04MM
Total Funding
$295.58MM
LFR Price per Share
$xx.xx
Last Funding Share Class
Series C
Endeavor BioMedicines Stock FAQs
To buy and sell Endeavor BioMedicines stock
Can you buy Endeavor BioMedicines stock?
As Endeavor BioMedicines is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Endeavor BioMedicines, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
How to buy Endeavor BioMedicines stock?

To invest in a private company like Endeavor BioMedicines through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
Can you sell Endeavor BioMedicines stock?
Yes, you may sell the Endeavor BioMedicines stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
How to sell Endeavor BioMedicines stock?

If you hold private company shares of Endeavor BioMedicines – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Endeavor BioMedicines on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
To learn more about Endeavor BioMedicines stock
Is Endeavor BioMedicines a public company?
No, Endeavor BioMedicines is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
What is Endeavor BioMedicines’ stock price?
Endeavor BioMedicines is a privately held company and therefore does not have a public stock price. However, you may access Endeavor BioMedicines private market stock price with Forge Data.
What is Endeavor BioMedicines’ stock ticker symbol?
Endeavor BioMedicines does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Endeavor BioMedicines Investors Also Invested in These Private Companies

Velosity Capital
Silver Arch Bio

Leadership & Board

Leadership

John Hood Ph.D
Co-Founder & Chief Executive Officer
Miguel de los Rios Ph.D
Co-Founder, President & Chief Scientific Officer
Vishaal Turakhia
Chief Financial Officer
Chris Krueger
Chief Operating Officer
Paul Frohna MD
Chief Medical Officer
Enoch Kariuki
President

Board

Andrew Lam
Ally Bridge Group
Bernard Davitian
Omega Funds
Brian Liu MD
Longitude Capital
Cindy Wang Ph.D
Longitude Capital
Karan Takhar
Matrix Capital Management
Monal Mehta Ph.D
Avidity Partners
Noelle Hutchins Ph.D
Omega Funds
Otello Stampacchia Ph.D
Omega Funds
Patrick Enright
Longitude Capital

Endeavor BioMedicines News and Media Highlights

Endeavor bags $132.5M series C, extending runway for clinical-stage fibrosis drugs through 2026

In series C funding led by new investors such as AyurMaya, Endeavor raised $132.5 million.
Browse Insights
Other Companies Like Endeavor BioMedicines in the BioTech & Pharma Sector
Sector: Healthcare
Subsector: BioTech & Pharma
Last Funding Round
Company Forge Price Forge Price Change 5 Last Closed Trade Share Class Post-Money Valuation Price per Share Amount Raised
Affinia TherapeuticsAffinia Therapeutics----$xx.xxSeries B$365.7MM$xx.xx$110MM
Altos LabsAltos Labs----$xx.xxSeries C$6.33B$xx.xx$1.5B
ArsenalBioArsenalBio----$xx.xxSeries C$1.66B$xx.xx$327.5MM
BillionToOneBillionToOne----$xx.xxSeries D$1.25B$xx.xx$130.47MM
Colossal BiosciencesColossal Biosciences----$xx.xxSeries C$10.2B$xx.xx$200MM
Isomorphic LabsIsomorphic Labs----$xx.xx--------
LoyalLoyal----$xx.xxSeries B-5$428.44MM$xx.xx$17.49MM
OwkinOwkin----$xx.xxSeries B-1$1.46B$xx.xx$50MM
Precision NeurosciencePrecision Neuroscience----$xx.xxSeries C$542.69MM$xx.xx$102MM
Xaira TherapeuticsXaira Therapeutics----$xx.xxSeries A$2.65B$xx.xx$500MM

Updated on: Jan 17, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.